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Introduction 5 5
Cutaneous malignant melanoma is one of the most lethal forms of cancer. Its 1 3 8 injection. The B16F1 tumor, blood, stomach, pancreas, small intestine, colon, liver, Elmer, Waltham, MA, USA). To determine the effect of unlabeled ligand on the tumor 1 4 2 uptake, either 0.5 nmol or 0.05 nmol non-labeled DOTA-NAPamide was co-injected. The study protocol was approved by the local committee for animal care according to 1 4 6 the German law for the protection of animals. All applicable institutional and national 1 4 7 guidelines for the care and use of animals were followed. Positron emission This demonstrated that chelation with Ga did not affect the affinity of DOTA- NAPamide towards the MC1R receptor. tracer from the standard procedure showed a very low uptake into subcutaneously 2 1 5 grown B16/F1 tumor xenografts (0.78% IA/g). Removal of unlabeled DOTA-2 1 6
NAPamide led to a more than 8-fold increase in tumor uptake, with 7.0% IA/g in the 2 1 7 tumor for the purified 68 Ga-DOTA-NAPamide. Except for a moderate uptake in the 2 1 8 kidneys, all other tissues showed only a small uptake of the tracer, mostly below 2 1 9 0.5% IA/g. In animals treated with 68 Ga-DOTA-NAPamide produced by the standard 2 2 0 procedure, the kidney uptake was slightly higher compared to the purified tracer 2 2 1 (4.56% IA/g vs. 3.07% IA/g) ( Fig 3) . The effect of cold peptide mass was studied by injecting a constant amount of 2 3 0 purified 68 Ga-DOTA-NAPamide together with different amounts of unlabeled DOTA- NAPamide. Mice were injected with 5 MBq (~50 fmol) alone or with an additional 2 3 2 1,000-fold (50 pmol) or 10,000-fold (500 pmol) excess of unlabeled peptide. This 2 3 3 10,000-fold excess of unlabeled peptide corresponds to the molar ratio in the 2 3 4 standard protocol. The coinjection of DOTA-NAPamide led to significant loss of 2 3 5 uptake in the MC1R-expressing B16/F1 tumor xenografts ( Fig 4) . While purified 68 Ga-2 3 6 1 3 DOTA-NAPamide showed an uptake of 6.7% IA/g, coinjection of 50 pmol cold DOTA-2 3 7
NAPamide decreased the total uptake to 3.8% IA/g. 500 pmol coinjected peptide led 2 3 8
to an approximately 6-fold decrease to 1.1% IA/g (Fig 4) . purified, C purified + 1,000-fold excess of cold peptide, D purified + 10,000-fold 2 5 0 excess of cold peptide). Dynamic PET images were taken from 5 to 90 minutes after showed an increase in uptake of 68 Ga-DOTA-NAPamide for the purified and the injections with a 10,000-fold excess of unlabeled peptide, the tracer uptake was on a 2 5 5 similarly low level as for the unpurified tracer ( Fig 5 A and D) . Since the peptide is 2 5 6 excreted through the kidneys into the bladder, a high signal was observed in both purified 68 Ga-NAPamide + 1,000-fold excess of DOTA-NAPamide, and E HPLC-2 6 3 purified 68 Ga-NAPamide + 10,000-fold excess of DOTA-NAPamide. To obtain kinetic profiles, mice were imaged for up to 90 minutes after injection of 2 6 7 either of the four different tracer formulations. Images were reconstructed over short 6A shows the kinetics for the purified 68 Ga-DOTA-NAPamide. After defining volumes 2 7 0 of interest (VOIs) for the tumor in each mouse, the resulting standardized uptake tumor confirm the advantage of tracer purification: in the first 5 -10 minutes after 2 7 3 injection, the tracer reaches a maximum level in the tumors for all tested conditions 2 7 4 ( Fig 6B) . Thereafter, uptake was slowly decreasing over the next 90 minutes. In the 2 7 5 animal treated with a 1,000-fold excess of cold peptide mass, the initial amount of 2 7 6 radioactivity in the tumor is slightly higher (SUV 0.63) than in the other tumors (mean 2 7 7 SUV 0.43). Of note, the slope of tracer decrease in B16/F1 tumors was less steep for 2 7 8 the purified 68 Ga-DOTA-NAPamide. NAPamide. Injected peptide amounts: 0.34 nmol (unpurified and 10,000-fold excess), The feasibility of targeting metastatic melanoma with MC1R ligands for nuclear 2 8 7 medicine has been studied as early as 1990 and has since resulted in a multitude of tumor uptake values ranging from 7.56% to 9.43% IA/g at 4 h p.i.[10] The 2 9 2 radionuclides used were of moderate half-life (2.81 d for 111 In, 3.26 for 67 Ga). Another PET imaging yet not reporting biodistribution data for the B16/F10 tumors used.
[12] 2 9 6
However, no clinical study has been reported for the use of MC1R analogs in 2 9 7 melanoma imaging so far. In experiments preceding this study, we performed biodistribution studies using the 2 9 9 MC1R ligands 68 Ga-DOTA-NDP-MSH and 68 Ga-DOTA-NAPamide in the B16/F1 3 0 0 melanoma model, yet failed to achieve the high tumor uptake previously reported for 3 0 1 the longer-lived 111 In and 67 Ga complexes. We hypothesized that the unfavorable 3 0 2 stoichiometry of the chelation reaction of the peptide conjugate with 68 Ga and the 3 0 3 resulting high excess of unlabeled ligand prevented higher tumor uptake due to 3 0 4 competition for MC1R binding sites. Therefore, in the current study we aimed to 3 0 5 compare a standard 68 Ga labeling protocol against a labeling and HPLC-purification protocol, which removes the excess of unlabeled peptide. We investigated the For the standard labeling protocol used in this study, the product of 350 MBq 68 Ga-3 1 0 DOTA-NAPamide (3.4 pmol 68 Ga) is accompanied by 34 nmol (50 µg) of unlabeled 3 1 1 peptide, resulting in a 10,000-fold excess over the radioligand. Due to this 3 1 2 stoichiometry, the theoretical molar activity of 103.000 GBq/µmol for pure 68 Ga-
DOTA-NAPamide is diminished to an effective molar activity of just 10 Gbq/µmol. Lowering the peptide amount in the chelation reaction was no remedy as it 3 1 5 dramatically reduces the radiochemical yield. HPLC purification of the radiopeptide, however, improved tumor uptake in 3 1 7 biodistribution studies by a factor of more than 8-fold, resulting in a tumor-to-kidney 3 1 8 ratio of 2.33 and tumor-to-tissue ratios of better than 15 for all organs investigated practice and developed solid phase extraction of 68 Ga-exendin as an alternative 3 2 1 method [13], we found using an HPLC to fractionate tracer was feasible and efficient. As most radiochemical laboratories have this instrumentation in place for routine 3 2 3 quality control, cost may not be limiting. The procedure can also be performed rapidly -within 15 to 20 min. Similar successful approaches to purify 11 C, 18 F and 67 Ga 3 2 5 tracers have been reported.[14-16] However, with production of 68 Ga tracers shifting 3 2 6 towards kit preparation, HPLC purification may not have much clinical future. In 3 2 7 addition, the enhancement of molar activity may not be of critical importance for the 3 2 8 imaging of humans as the applied amount of activity (and thus, peptide) is several 3 2 9 orders of magnitude lower than for rodents. The appropriate amount of cold peptide mass or the best molar activity for optimal 3 3 1 tumor imaging has been a matter of investigation for more than two decades now. Using the somatostatin receptor ligand 111 In-pentetreotide, an early study by per mouse showed highest tumor uptake (10.9% IA/g), with 5, 45 and 135 pmol 3 4 5 yielding somewhat lower results (7.98, 8.0, 6.25% IA, respectively). Of note, intestines showed a continuously decreasing % IA/g uptake with increasing amounts 300-fold higher than the administered amount of 111 Indium-labeled exendin. The Chelators with higher labeling efficiency than DOTA may represent an alternative 3 6 7 approach to obtaining high molar activities. Recently, the effect of varying molar 3 6 8 activities (0.5 -1,000 GBq/µmol) was studied for the two integrin-targeting 68 Ga- with similar tumor-to-kidney ratios for all tested conditions. However, tumor-to-muscle 3 7 4 ratios reached a maximum at 6 nmol (~3.5 GBq/µmol), indicating a benefit for 3 7 5 moderate molar activities when muscle signal is limiting.
[12] A variety of factors may 3 7 6 lead to this, including target expression levels in muscle and other organs. Further 3 7 7 studies will have to elucidate the relationship between expression, biodistribution and 3 7 8 optimal molar activity for tumor imaging. Choosing the right molar activity and finding a way to obtain it in an efficient way 3 8 4 remains to be a challenge during the introduction of new tracers. We showed that imaging, but may also improve uptake and thus efficacy in therapeutic procedures 3 9 1 such as PRRT. Research (BMBF grant IPT614A to CG), and in part by the Deutsche 
